West Pharmaceutical Services, Inc. (WST)

NYSE: WST · IEX Real-Time Price · USD
337.75
-1.09 (-0.32%)
At close: Aug 11, 2022 4:04 PM
342.00
+4.25 (1.26%)
Pre-market: Aug 12, 2022 8:25 AM EDT
-0.32%
Market Cap 25.01B
Revenue (ttm) 2.93B
Net Income (ttm) 685.60M
Shares Out 74.05M
EPS (ttm) 8.97
PE Ratio 37.65
Forward PE 37.04
Dividend $0.72 (0.21%)
Ex-Dividend Date Jul 19, 2022
Volume 210,960
Open 340.87
Previous Close 338.84
Day's Range 337.26 - 347.13
52-Week Range 275.89 - 475.35
Beta 1.15
Analysts Buy
Price Target 394.23 (+16.7%)
Earnings Date Jul 28, 2022

About WST

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhanc... [Read more...]

Industry Health Care Equipment & Supplies
Founded 1923
CEO Eric Green
Employees 10,065
Stock Exchange NYSE
Ticker Symbol WST
Full Company Profile

Financial Performance

In 2021, WST's revenue was $2.83 billion, an increase of 31.89% compared to the previous year's $2.15 billion. Earnings were $661.80 million, an increase of 91.16%.

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for WST stock is "Buy." The 12-month stock price forecast is 394.23, which is an increase of 16.72% from the latest price.

Price Target
$394.23
(16.72% upside)
Analyst Consensus: Buy
Stock Forecasts

News

West Makes Minority Investment in Dublin-Based Latch Medical, a Developer of Vaccine and Biologics Delivery Platforms

EXTON, Pa. , Aug. 11, 2022 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced it has made a strat...

West Pharmaceutical (WST) Q2 Earnings Beat, FY22 View Cut

West Pharmaceutical's (WST) second-quarter earnings reflect strength in the Proprietary Products segment.

West Pharmaceutical Services (WST) Q2 Earnings and Revenues Surpass Estimates

West Pharmaceutical (WST) delivered earnings and revenue surprises of 12.79% and 2.44%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

West Announces Second-Quarter 2022 Results

- Conference Call Scheduled for 9 a.m. EDT Today - EXTON, Pa.

West Elects New Director to the Board

EXTON, Pa. , July 27, 2022 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, announced today the Company's Board...

What's in Store for West Pharmaceutical (WST) in Q2 Earnings?

West Pharmaceutical's (WST) second-quarter results are likely to reflect strength in the Proprietary Products business.

West to Host Second-Quarter 2022 Conference Call

EXTON, Pa. , July 14, 2022 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will releas...

West Pharmaceutical Services Releases 2021 Corporate Responsibility Report

EXTON, Pa. , July 12, 2022 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, has recently released its 2021 Corp...

West Pharmaceutical Services (WST) is a Top-Ranked Growth Stock: Should You Buy?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why You Should Retain West Pharmaceutical (WST) Now

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex woes persist.

West Pharmaceutical's (WST) Syringe System to Improve Outcome

West Pharmaceutical's (WST) new CZ syringe system size is expected to enable a simpler patient experience and aid pharmaceutical companies in providing better access to their products.

West Introduces Daikyo Crystal Zenith® 2.25mL Insert Needle Syringe System at BIO International Convention

EXTON, Pa. , June 13, 2022 /PRNewswire/ -- West Pharmaceutical Services, Inc.  (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will unvei...

West Receives Exhibitor Award at INTERPHEX 2022 for Proprietary DeltaCube™ Modeling Platform

The DeltaCube™ Modeling Platform is an analytics platform aimed at container closure system (CCS) selection, optimization, and usage EXTON, Pa. , May 24, 2022 /PRNewswire/ -- West Pharmaceutical Service...

West to Attend and Showcase Industry Leadership in Packaging and Containment at INTERPHEX 2022

West to present on industry trends, enabling technologies, packaging components, and innovative DeltaCube™ Modeling Platform EXTON, Pa. , May 23, 2022 /PRNewswire/ -- West Pharmaceutical Services, Inc. ...

Here's Why West Pharmaceutical Services (WST) is a Strong Growth Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

West Announces Executive Leadership Appointments

EXTON, Pa. , May 12, 2022 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, announced today the appointment of W...

West to Participate in Upcoming Investor Conferences

EXTON, Pa. , May 3, 2022 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will particip...

West Pharmaceutical (WST) Q1 Earnings Top Estimates, Revenues Lag

West Pharmaceutical's (WST) first-quarter earnings reflect strength in the Proprietary Products segment and operating margin expansion.

West Pharmaceutical Services Shares Slides Post Q1 Results

West Pharmaceutical Services Inc (NYSE: WST) reported first-quarter FY22 sales growth of 7.4% year-on-year to $720 million, missing the consensus of $720.92 million. Proprietary products segment revenue...

West Pharmaceutical Services (WST) Q1 Earnings Top Estimates

West Pharmaceutical (WST) delivered earnings and revenue surprises of 5.50% and 0.63%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

West Announces First-Quarter 2022 Results and Declares Third-Quarter 2022 Dividend

- Conference Call Scheduled for 9 a.m. EDT Today - EXTON, Pa.

What's in Store for West Pharmaceutical's (WST) Q1 Earnings?

West Pharmaceutical's (WST) first-quarter results are likely to reflect strength in the Proprietary Products business.

West to Host First-Quarter 2022 Conference Call

EXTON, Pa. , April 14, 2022 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will relea...

Pneuma Systems collaborates with West Pharmaceutical Services, Inc. to improve the patient experience

PORTSMOUTH, N.H. , April 7, 2022 /PRNewswire/ -- Medical technology company, Pneuma Systems Corporation, has entered a multi-faceted business collaboration with West Pharmaceutical Services, Inc. (NYSE:...

West Receives Fred Simon Award and Edward Smith Packaging Science Award at 2022 PDA Annual Meeting

EXTON, Pa. , April 4, 2022 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that its Scientific...